# US 9,884,104 B2 · Live attenuated virus vaccines for la crosse virus and other bunyaviridae

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,884,104 B2
- Document ID: US9884104B2
- Status: Granted
- Kind: B2
- Application number: 15/018,857
- Filed: 2016-02-08
- Published: 2016-12-22
- Granted: 2018-02-06
- Earliest claimed: 2007-03-29
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Stephen S. Whitehead; Richard S. Bennett; Brian R. Murphy
- Web page: https://patentgrep.com/patent/US9884104B2

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/701: {Specific hybridization probes}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2760/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACY) infection in a biological sample and infectious chimeric Bunyaviridae.

## Claims

### Claim 1

An immunogenic composition comprising a La Crosse virus polypeptide or a nucleic acid molecule encoding same, wherein said La Crosse virus polypeptide comprises a mutation at amino acid 148 of GN.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the mutated amino acid at position 148 of GN is Alanine.

### Claim 3 (depends on 1)

The composition of claim 1, wherein amino acid 148 of GN is deleted.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the mutated amino acid at position 148 of GN is any amino acid other than Threonine.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said LACV polypeptide is a LACV/human/1960 virus sequence, LACV/mosquito/1978 virus sequence, or a LACV/human/1978 virus sequence.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said LACV polypeptide sequence has at least about 85%, 88%, 90%, 92%, 95%, 97%, 98%, 99%, or 99.9% amino acid identity to an amino acid sequence of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said nucleic acid molecule is codon-optimized for expression in humans.

### Claim 8 (depends on 1)

A method of inducing an immune response against an LACV infection in a mammal, comprising administering to said mammal a therapeutically effective amount of the composition of claim 1.

### Claim 9 (depends on 1)

A method of producing an immunogenic composition for inducing an immune response against an LACV, comprising the steps of providing the composition of claim 1; and formulating said composition for delivery to a human.